553631-38-2

Basic information

• Product Name: TERT-BUTYL 4-CYANO-4-(4-METHOXYPHENYL)PIPERIDINE-1-CARBOXYLATE
• Synonyms: TERT-BUTYL 4-CYANO-4-(4-METHOXYPHENYL)PIPERIDINE-1-CARBOXYLATE;1-Boc-4-cyano-4-(4-methoxyphenyl)-piperidine
• CAS NO: 553631-38-2
• Molecular Formula: C₁₈H₂₄N₂O₃
• Molecular Weight: 316.39
• Mol File: 553631-38-2.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: TERT-BUTYL 4-CYANO-4-(4-METHOXYPHENYL)PIPERIDINE-1-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 4-CYANO-4-(4-METHOXYPHENYL)PIPERIDINE-1-CARBOXYLATE(553631-38-2)
• EPA Substance Registry System: TERT-BUTYL 4-CYANO-4-(4-METHOXYPHENYL)PIPERIDINE-1-CARBOXYLATE(553631-38-2)

Safety Data

• Hazardous Substances Data: 553631-38-2(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 104-47-2 p-methoxybenzylnitrile 
• 118753-70-1 N-(tert-butyloxycarbonyl)bis(2-chloroethyl)amine 

Downstream Products

• 1158750-72-1 1-(tert-butoxycarbonyl)-4-(4-methoxyphenyl)piperidine-4-carboxylic acid 

Relevant articles and documents

A nitrogen-containing heterocyclic phenyl piperidine compound and its preparation method and application

The invention discloses a nitrogen-containing heterocyclic phenyl piperidine compound or pharmaceutical salt thereof. The general structural formula a of the compound is as shown in specification, wherein R represents hydrogen, mono-substituted or poly-substituted halogen, methyl, methoxyl, tertiary butyl or trifluoromethyl; and R2 is hydrogen, chlorine, bromine, methyl or ethyl. The compound disclosed by the invention is novel in structure; and by introducing the active amino in the form of a piperidine ring, the configuration of the side-chain amino is reinforced and the rigidity of the compound is enhanced. Through the design transformation, the Akt1 kinase inhibitory activity and the PC-3 cell line growth inhibitory activity of the compound are significantly enhanced.

Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use

The subject invention provides compounds having the structure: 1 wherein,R1 is a substituted or unsubstituted alkyl, wherein the substituent is hydroxyl, dihydroxy, carboxyl, —C(═O)NRaRb, —NRaRb, —NRaC(═O)NRaRb, —NRaC(═O)ORa, —OC(═O)NRaRb, or —NHC(═O)Ra;R2 is hydrogen or a substituted or unsubstituted alkyl, wherein the substituent is hydroxyl, dihydroxy, carboxyl, —C(═O)NRaRb, —NRaRb, —NRaC(═O)NRaRb, —NRaC(═O)ORa, —OC(═O)NRaRb, or —NHC(═O)Ra, orR1, R2 and N together form a substituted piperazine, substituted azetidine ring, or a pyrrolidine ring substituted with —(CH2)2OH or —CH2C(═O)OH;R3 is a substituted or unsubstituted phenyl or a 5-6 membered heteroaryl ring, wherein the substituent is halogen, hydroxyl, cyano, (C1-C15)alkyl, (C1-C15)alkoxy, or —NRaRb;R4 is hydrogen or substituted or unsubstituted (C1-C15)alkyl;R5 is —(CH2)mOR6, —CHNOR7, —C(═O)NR8R9, —(CH2)mC(═O)OR10, —(CH2)kC(═O)NR11R12;wherein R6 is a substituted or unsubstituted (C1-C30)alkyl, (C3-C10)cycloalkyl, or an aryl, heteroaryl or 4-8 membered heterocyclic ring;R7 is hydrogen, or a substituted or unsubstituted (C1-C30)alkyl, (C1-C30)alkylaryl;R8 and R9 are each independently hydrogen, or a substituted or unsubstituted (C1-C30)alkyl, (C1-C30)alkylaryl, (C1-C30)alkylamino, (C1-C30)alkoxy, or a saturated or unsaturated, monocyclic or bicyclic, carbocyclic or heterocyclic ring, orR8, N, and R9 together form a substituted or unsubstituted 4-8 membered heterocyclic ring;R10 is hydrogen or a substituted or unsubstituted (C1-C30)alkyl, (C3-C10)cycloalkyl, or an aryl, heteroaryl or heterocyclic ring;R11, N and R12 together form a 4-8 membered heterocyclic ring;Ra and Rb are each independently hydrogen or alkyl;m is 0, 1, 2 or 3; andk is 1, 2 or 3,or a specific enantiomer thereof, or a specific tautomer thereof, or a pharmaceutically acceptable salt thereof, and a method for treating a disease associated with the A2b adenosine receptor in a subject in need of such treatment comprising administering to the subject a therapeutically effective amount of the compounds of the invention.